Sai Life Sciences Limited announced its unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2026. The company also approved the appointment of new Senior Management Personnel and the allotment of 108,005 equity shares upon exercise of employee stock options. The equity share capital has increased post-allotment.
Sai Life Sciences Reports Financial Performance and Key Approvals
Sai Life Sciences Limited held a Board Meeting on November 5, 2026, to consider and approve several key matters. The Board reviewed and approved the unaudited standalone and consolidated financial results for the second quarter and the half year ended September 30, 2026. Correspondingly, limited review reports for these results were also approved.
Leadership Appointments
Following the recommendation of the Nomination and Remuneration Committee, the Board approved the appointment of three individuals as Senior Management Personnel (SMP) effective November 5, 2026. These appointments include:
- Mr. Sidhartha Das as Senior Vice President & Head – Human Resources
- Mr. Vijay Kumar Suthari as Vice President – Head Quality & Regulatory Affairs
- Mr. Sriram Gopalakrishnan as Senior Vice President – Corporate Communications
Brief profiles detailing their experience and qualifications are provided in Annexure-A.
Equity Share Allotment and Capital Increase
The Board also approved the allotment of 27,005 and 81,000 fully paid-up equity shares, totaling 108,005 shares, upon the exercise of options granted under the Employees Stock Option Plan 2008 (ESOP 2008) and Management Employee Stock Option Plan 2018 (MESOP 2018). As a consequence of this allotment, the company’s issued, subscribed, and paid-up equity share capital has increased from ₹21,24,72,716 to ₹21,25,80,721.
Financial Highlights (Standalone)
For the quarter ended September 30, 2026, Sai Life Sciences reported total income of ₹6,509.18 million and profit after tax of ₹960.13 million. For the six months ended September 30, 2026, total income stood at ₹12,011.90 million, with profit after tax at ₹1,673.52 million.
Financial Highlights (Consolidated)
On a consolidated basis, for the quarter ended September 30, 2026, total income was ₹6,625.54 million, and profit after tax was ₹983.17 million. For the six months ended September 30, 2026, consolidated total income reached ₹12,203.82 million, with profit after tax at ₹1,716.02 million.
Auditor’s Review
The unaudited financial results were reviewed by the Audit Committee and approved by the Board. The results have also been reviewed by Deloitte Haskins & Sells LLP, the statutory auditors, who have issued an unmodified conclusion.
Source: BSE
